Haemonetics (NYSE:HAE) today announced the first patients treated with its Vascade MVP venous vascular closure system in Germany.
Boston-based Haemonetics said this marks the first use of the Vascade portfolio — widely used in the U.S. — in a European country.
The company designed Vascade for small-bore femoral arterial and venous closure. Its general uses include interventional cardiology and peripheral vascular procedures. Haemonetics developed Vascade MVP for mid-bore multi-access femoral venous closure, generally used in electrophysiology procedures.
Both closure devices hold CE mark approval in Europe. They cover patients who have undergone catheter-based procedures with single or multiple access sites in one or both limbs and include proprietary collapsible disc technology and a resorbable collagen patch to achieve hemostasis.
Haemonetics says its Vascade and Vascade MVP systems can save time for hospital staff and help patients reach hemostasis faster. Its design also leads to fewer complications on average compared to manual compression.
The company plans for further expansion for its Vascade portfolio in other markets outside the U.S. Following the German launch, the company also released its Vascade systems in Italy. Haemonetics also began distributing its Vascade MVP system in Japan, with a launch slated for later this year.
“International commercialization of our Vascade portfolio represents an exciting milestone for our vascular closure business, reinforcing our industry leadership in improving hospital operations and raising standards of care for patients,” said Stewart Strong, president, global hospital at Haemonetics. “We look forward to continuing to expand our presence in global interventional cardiology and electrophysiology markets to meet the ongoing needs of physicians throughout the world.”